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ABSTRACT 
 Patients with chronic kidney disease (CKD) exhibit a disproportionate burden of 
cardiovascular disease and other comorbid conditions compared to the general 
population. It is speculated that this increased burden of comorbid conditions is partially 
driven by the systemic accumulation of gut-derived bacterial byproducts and the 
ensuing activation of innate immune pathways. As a result, researchers have directed 
their attention to the intestinal microbiome as a novel therapeutic target for reducing 
morbidity and mortality in CKD patients.   
 In this dissertation, I will first summarize the current state of knowledge regarding 
the complex interactions between the intestinal microbiota and gut barrier function, 
highlighting how intestinal bacteria and components of the intestinal barrier contribute to 
the maintenance of an immune tolerant environment. Next, I will review the existing 
literature regarding the contribution of intestinal dysbiosis to chronic disease states, 
including CKD. Lastly, I will review the findings from my own experiments focused on: 
(1) determining how CKD alters the metabolism of trimethylamine N-oxide (TMAO), a 
novel uremic toxin that correlates with cardiovascular risk in CKD, and (2) characterizing 
how CKD impacts the expression patterns and activity of intestinal and hepatic alkaline 
phosphatases, a group of enzymes involved in the detoxification bacterial endotoxins 
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CHAPTER 1: INTRODUCTION 
Clinical Implications of Chronic Kidney Disease 
A major function of the kidney is to maintain homeostasis by excreting excess 
metabolites and waste products from the blood. This is achieved by the coordinated 
action of approximately 1 million nephrons per kidney (1). Bulk filtration of the blood 
occurs at the glomerulus, a tuft of capillaries encapsulated by Bowman’s capsule, while 
fine-tuning of the filtrate occurs throughout the remaining nephron segments to produce 
the final urine product. Kidney function is assessed by calculating the estimated 
glomerular filtration rate (eGFR) of a substance that is predominately filtered by the 
glomerulus and not further handled by the downstream nephron. Most often in the clinic, 
a patient’s eGFR is calculated based on measurements of their serum and urine 
creatinine concentrations (2). Patients with normal kidney function have an eGFR of 
roughly 120 mL/min, resulting in 180 L of blood being filtered by the kidneys per day. 
Common risk factors for the development of chronic kidney disease (CKD) 
include obesity, diabetes, metabolic syndrome, and hypertension; therefore, the 
increasing prevalence of Western diet consumption and a sedentary lifestyle among 
Americans has resulted in a growing number of individuals developing kidney disease in 
the United States (3). CKD is characterized by the progressive and irreversible decline 
in kidney function, and CKD severity is classified into five stages, largely based on 
eGFR values. At CKD stage 3 (an eGFR ~60 ml/min), a patient’s glomerular filtration 
has declined by at least 50%, resulting in the accumulation of biological waste products 
that exhibit toxicity to a variety of organ systems. A patient with minimal residual kidney 
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function (<10%) is considered to have end-stage renal disease (ESRD) and must 
receive either chronic dialysis therapy or a kidney transplant in order to survive. 
CKD patients are at an increased risk of developing numerous comorbid 
diseases, most notably, cardiovascular disease (CVD). Moreover, the increased risk of 
CVD observed in CKD patients persists after the adjustment for traditional risk factors, 
such as diabetes and hypertension (4). Researchers hypothesize that uremic toxins, 
metabolites that accumulate in the setting of decreased renal clearance, and a pro-
inflammatory phenotype, both contribute to pathological changes that promote more 
aggressive CVD development in patients with impaired kidney function. While a subset 
of these uremic toxins are metabolites formed by the processing of dietary constituents 
by intestinal bacteria, others are pro-inflammatory bacterial byproducts that likely gain 
entry to the portal circulation through intestinal barrier defects.  
The purpose of this dissertation is to examine how alterations to the intestinal 
microenvironment in CKD may contribute to the pathophysiology of comorbid 
conditions, such as CVD, that are highly prevalent in CKD patients.  
Intestinal Microbiota  
The intestinal microbiota is composed predominantly of bacteria belonging to 
Firmicutes and Bacteroidetes phyla, but other organisms such as achaea, viruses and 
fungi are also present. The exact composition of the intestinal microbiota is dependent 
on the anatomical location within the digestive tract. For example, due to the acidic 
environment, few microorganisms are found within the stomach, and the number of 
bacteria increases dramatically moving distally to the colon (5). Furthermore, host diet 
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can have a substantial impact on intestinal microbiota composition that is at least 
partially dependent on dietary protein and carbohydrate intake (6).  
With nearly 1 trillion cells, culminating to 150 more genes than expressed by 
mammalian systems (7), the intestinal microbiota performs indispensable functions to 
maintain normal host physiology such as, metabolizing complex polysaccharides to 
produce short-chain fatty acids (SCFA) and synthesizing crucial vitamins (8,9). These 
microorganisms are imperative for both intestinal and immune system	development. 
Germ free mice, void of intestinal microbiota, have gross morphological abnormalities of 
their intestine (10-12) and a naïve immune system that is unable to properly generate 
an immune response (13). Additionally, the importance of the intestinal microbiota in the 
developing intestine is highlighted by the ‘hygiene hypothesis’. This hypothesis states 
that the increasing incidence of autoimmune diseases in developed counties is due to 
decreased exposure to bacteria in early life, resulting in improper education of the 
immune system (14).  
Intestinal Barrier 
The digestive tract is one of the most immunologically active organs, and due to 
the constant exposure to bacteria and other microorganisms within the digestive tract, 
the body has developed a complex barrier system to maintain a sterile systemic 
environment (Figure 1.1 A). The three layers of the intestine include the mucosa 
(luminal side), submucosa, and muscular layer. The mucosa is composed of intestinal 
epithelial cells (IEC) and the lamina propria. The architecture of the small intestine 
includes finger-like projections, villi, and crypts to increase surface area and promote 
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absorption of nutrients. The intestinal submucosa contains blood vessels and nerves, 
while the muscular layer is crucial for peristalsis.  
As depicted in Figure 1.1 A, the mucus layer adjacent to the mucosa is 
composed of mucin proteins and acts as an initial physical barrier for microorganisms. 
Within the mucus layer, antimicrobial peptides (AMP), secreted by Paneth cells, and 
soluble IgA, secreted by plasma cells that reside in the lamina propria, maintain a 
relatively sterile environment adjacent to the intestinal epithelium. Next, tight-junction 
complexes between IEC do not allow for the paracellular transport of large molecule 
such as bacteria or bacterial byproducts (Figure 1.1 B). Lastly, cells of both the innate 
and adaptive immune systems reside within the lamina propria (Figure 1.1 C). As 
described above, terminally differentiated plasma cells secrete soluble IgA and T cell 
populations secrete various cytokines and factors. Other cells of the innate immune 
system that reside in the lamina propria include macrophages with phagocytic 
capabilities and dendritic cells with antigen-presenting capabilities. Commensal bacteria 
can promote the maintenance of the intestinal barrier, along with each component of the 
barrier regulating one another. As just one example, the overexpression of the 
antimicrobial peptide (AMP) results in a thicker mucus layer that bacteria cannot 





Figure 1.1 Schematic of the intestinal barrier. (A) The three layers of the intestine 
include the mucosa, submucosa, and muscle layer. The body has developed numerous 
mechanisms to maintain immune tolerance and prevent bacteria from entering into 
systemic circulation. The mucus layer, containing antimicrobial peptides (AMP) and 
soluble IgA (SIgA), is a relative sterile environment (16). (B) Tight junction complexes 
between intestinal epithelial cells prevent the paracellular transport of bacteria or 
bacterial endotoxins from entering into the circulation. (C) The lamina propria just 
underneath the intestinal epithelial cells contains cells from the innate and adaptive 




Role of Intestine in Disease 
As described above, the intestinal barrier and immune system have developed a 
complex network to maintain normal physiologic homeostasis and prevent exposure to 
the numerous inflammatory stimuli that reside in the gut lumen. If mechanisms are lost 
to maintain immune tolerance, sporadic disease can occur as observed in the IL10-/- 
mouse. IL10 is an anti-inflammatory cytokine involved in maintaining immune tolerance 
within the intestine, and when void of this cytokine, sporadic inflammatory bowel 
disease develops. Interestingly, when the IL10-/- mouse lacks intestinal bacteria, no 
disease of the intestine occurs (17). Likewise, genetic mutations linked to inflammatory 
bowel disease, including alterations to NOD2 and JAK-STAT signaling, lead to defects 
in bacterial sensing and subsequent immune responses (18).  
Transgenic overexpression of myosin light-chain kinase, which results in the loss 
of tight junction integrity and increased intestinal permeability, is not sufficient to cause 
intestinal disease, despite observing a mucosal immune response in this setting (19). In 
numerous chronic diseases, it is believed that subtle shifts in intestinal microbiota 
composition and alterations to barrier function do not lead to an outright inflammatory 
phenotype within the intestine, but rather, these changes provide an environment that is 
more amenable to translocation of luminal contents into the systemic circulation to 
trigger pro-inflammatory cascades. 
Bacterial Endotoxin: As will be described below, a majority of chronic diseases 
are characterized by a pro-inflammatory phenotype that may be due to the translocation 
of bacteria and bacterial endotoxins into systemic circulation. Endotoxins are 
components of bacteria that accumulate due to bacterial cell death and can elicit an 
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immune response through binding of pattern recognition receptors of the innate immune 
system. Lipopolysaccharide (LPS) is the most extensively studied endotoxin, and is a 
component of the bacterial wall of gram-negative bacteria. The structure of LPS 
includes an O-antigen, a polysaccharide core, and a lipid A component. The O-antigen 
is the most variable region of LPS and is used by different bacterial species to evade 
immune recognition. By contrast, the lipid A motif is imperative for binding to the LPS 
receptor, toll-like receptor 4 (TLR4), to stimulate an inflammatory response (20,21). 
Increased systemic LPS is most notably associated with metabolic syndrome and 
associated conditions (22).  
Aging: Increased intestinal permeability is an evolutionarily conserved hallmark 
of aging observed in Drosophila, C. elegans, mice, and humans. In Drosophila, 
increased intestinal permeability was a better predictor of mortality than chronological 
age (23). Furthermore, in these invertebrate models, shifts in intestinal microbiota 
composition occurred before increased intestinal permeability (24). In mammalian 
systems, an aged intestine begins secreting more pro-inflammatory cytokines (25), 
many of which have been shown to disrupt intestinal epithelium tight junction complexes 
(26,27). While there have been no gross abnormalities observed in the mucus layer 
lining of an aged intestine, Paneth cell numbers decline and are associated with 
reduced AMP secretion (28), and increased bacterial adhesion to the mucus layer (29). 
Lastly, investigators have observed an age-related decline in antigen presenting cells in 
the lamina propria, resulting in impaired T cell priming (30). Chronic diseases share 
many similarities to the aging process, and a common link appears to be increased 
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intestinal permeability. It may be possible that treatments targeting the gut could be a 
therapeutic tool utilized for several of these conditions  
Western Diet: Diet is a well-recognized risk factor for the development of chronic 
diseases. A Western diet, characterized by consumption of highly processed foods with 
high saturated fat content, promotes intestinal inflammation (31) and increased 
intestinal permeability (32,33) resulting in increased serum LPS levels. This disease 
state, termed metabolic endotoxemia, leads to insulin insensitivity, fatty liver disease, 
and increased risk of CVD development. Additionally, Lee et. al. described a decrease 
in Paneth cell and goblet cell number with consumption of a high-fat diet (33). Moreover, 
as diet and microbiota composition are intimately linked, these anatomical changes may 
be due to changes in gut bacterial species with consumption of a high fat diet (34). It is 
noteworthy that germ free mice do not become obese when fed a high fat diet (35,36).  
Liver Disease: Gut luminal content absorbed into the bloodstream enters into 
the portal vein and is handled first by the liver before continuing on to the systemic 
circulation. Due to this intimate relationship, it is understandable that patients with liver 
disease would exhibit intestinal dysbiosis. Alcoholic liver disease is associated with 
small intestinal bacterial overgrowth, reduced colonic bacteria (37), and low-grade 
endotoxemia (38,39). One hypothesis among researchers is that acetaldehyde, a toxic 
metabolite generated by the metabolism of ethanol, drives shifts in the intestinal 
microbiota and increases intestinal permeability by disrupting the tight-junction integrity 
between IEC (40). In addition to decreased tight-junction protein expression, a 
thickened mucus layer is observed in mice and humans after chronic alcohol exposure 
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(41). Intestinal changes are also observed in non-alcoholic liver disease (42) and 
cholestasis induced by bile duct ligation (43). 
Diabetes: In addition to diseases associated with life-style factors, alterations to 
the intestinal microbiota and immune system have been implicated in autoimmune 
diseases; such as, type 1 diabetes (T1D). Early studies in T1D rodent models revealed 
that before the onset of insulin resistance, there is an increase in intestinal permeability, 
increased intestinal immune infiltration, and a decline in natural killer cell number and 
function within the intestine (44-46). A clinical study explored the serum levels of 
zonulin, a protein that negatively regulates intestinal permeability, in patients with T1D. 
The authors of this study concluded that there was an upregulation of zonulin in patients 
with T1D compared to healthy controls. Furthermore, increased serum zonulin levels 
were observed in a subset of patients in the pre-type 1 diabetes phase (47). In addition 
to local immunity, T1D researchers have explored alterations to the enteric nervous 
system. Briefly, T1D results in the loss of neuron number and overall motor function of 
the gut (48).  
Gut Microbiome Changes in CKD 
Studies conducted over 50 years ago examining the possible role of the 
microbiota in kidney disease elucidated that post-nephrectomy, germ-free rats survived 
significantly longer than conventionally raised rats (49). More recently, the presence of 
systemic bacteria and bacterial endotoxins were confirmed in uremic animal models 
(50-53) and in ESRD patients; these bacterial endotoxins were predictive of an 
enhanced inflammatory phenotype (54). Clinical studies, utilizing non-invasive 
measurements of intestinal permeability (urinary recovery of polyethylene glycols [PEG] 
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or plasma D-lactate measurements), suggest that ESRD patients may have increased 
intestinal permeability compared to healthy controls (55).  
To date, most of the studies investigating the intestinal environment in CKD have 
focused solely on shifts in the intestinal microbiota (56) and expression of tight-junction 
proteins in CKD animal models. For example, in the 5/6 nephrectomy model, rodents 
with reduced nephron mass exhibit decreased expression of the tight junction proteins, 
occludin, zona occludin-1 (ZO-1), and claudin-1, in whole tissue lysates of the stomach, 
jejunum, ileum, and colon (57,58). Additional evidence from in vitro studies 
demonstrated that serum from ESRD patients was capable of decreasing epithelial 
resistance and accompanying tight junction protein expression in T84 cells, a human 
enterocyte cell line (59). In a separate study utilizing these same T84 cells, applying 
urea alone resulted in diminished tight junction protein expression. Moreover, protein 
expression was further reduced when cells were exposed to urea in conjunction with 
urease, a bacterial enzyme capable of converting urea to ammonia. Based on these 
results, authors of this study hypothesized that an accumulation of urea within the 
digestive tract of patients and animals with CKD is being converted to ammonia that 
increases the pH of the intestinal tract, which in turn, disrupts tight junction protein 
complexes (60). There are certainly many other bacterial metabolites/toxins or local 
environmental factors that may contribute to diminished intestinal epithelial tight junction 
integrity in CKD (61).  
As described above, many uremic toxins that accumulate in CKD and are 
thought to have organ toxicity are derived from intestinal microbes. The two most widely 
studied uremic toxins of intestinal origin are the protein-bound solutes indoxyl sulfate 
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and p-cresyl sulfate. Indoxyl sulfate is derived from the amino acid tryptophan (62) and 
is primarily associated with kidney fibrosis (63), and vascular dysfunction (64,65). P-
cresyl sulfate, produced by bacterial metabolism of tyrosine and phenylalanine, is 
associated with adverse CVD outcomes and all-cause mortality (66,67). Other potential 
uremic toxins of intestinal origin that have been studied less extensively include 
phenylacetylglutamine (68), guanidine (69), and trimethylamine N-oxide (70). Lastly, 
metabolic shifts in the intestinal microbiota may result in increased capacity of the 
intestinal microbiota to produce uremic toxins and decreased capacity to produce SCFA 
(71-73). The changes observed in patients with CKD are summarized in Figure 1.2. 
Treatments Targeting the Gut Microbiome in CKD 
 Clinical strategies seeking to reduce circulating levels of uremic toxins and 
inflammation in CKD patients include protein restriction and renal replacement 
strategies; thus far, both have proved ineffective. In the past two decades, researchers 
have turned to therapies targeting the intestinal microbiota and intestinal environment. 
Therapies that have gained attention include oral adsorbents and probiotics. 
Unfortunately, as of now, no therapy has shown enough promise and safety to gain 
FDA approval.  
Oral adsorbents bind and promote the fecal excretion of uremic toxins. The most 
extensively studied adsorbent, is activated charcoal AST-120. This therapy restored 
colonic tight-junction protein expression in an adenine-induced CKD rat model (58), 
reduced a kidney fibrotic phenotype in a nephrectomized rat model of CKD (74), and 
even reduced the incidence of cardiac fibrosis in a rat model of CKD through 
attenuation of oxidative stress (75). AST-120 therapy reduced serum concentrations of 
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indoxyl-sulfate in uremic animals and in a phase II clinical trial in humans (58,74,76). 
However, in the Evaluating Prevention of Progression in CKD (EPPIC) study, a phase III 
trial investigating the effect of AST-120 on CKD progression, there was no obvious 
impact of this therapy on CKD progression; thus, this drug has failed to gain FDA 
approval. A major limitation to this study was that the placebo-treated group had slower 
than expected disease progression, making it difficult to observe any significant 
differences with AST-120 treatment (77). It is noteworthy, that AST-120 therapy is 
approved and extensively used in Japan as a possible mechanism for delaying the time 
to renal replacement therapy. Reported adverse events with AST-120 therapy include 
constipation, appetite loss, and nausea (78).  
Another strategy to reduce uremic toxins and inflammation is the administration 
of probiotics, live bacteria that confer a health benefit to the host. Several bacterial 
strains can be administered simultaneously to achieve multiple endpoints of interest. 
Probiotics can confer benefit to the host through several mechanisms, including 
competing for environmental resources with other bacterial strains to reduce the growth 
of pathologic bacteria (79), or by affecting host biology through actions such as 
stimulating the production of mucins (80), enhancing tight-junction integrity (81), 
promoting the production of antimicrobial peptides (82), or reducing the pH of the 
digestive tract (83,84). 
A promising use for probiotic therapy in CKD would be the administration of 
bacteria that could metabolize specific uremic toxins or target metabolic pathways 
involved in uremic toxin production. This could be achieved through administering 
several bacterial strains simultaneously, or genetic engineering to produce bacteria that 
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express enzymes of interest. While strategies such as microencapsulation of probiotics 
have significantly improved the effective delivery of these therapies to patients (85,86), 
special consideration will need to be taken into account when designing probiotic 
therapy for treatment of CKD patients, since this population exhibits unique biochemical 
parameters (i.e. chronic acidosis) and altered intestinal physiology (i.e. decreased 
transit time) that may affect the successful colonization of probiotic species.  
Gaps in Knowledge 
 In CKD, researchers believe that uremia results in shifts of the intestinal 
microbiota composition leading to increased capacity to generate uremic toxins. Shifts 
in intestinal microbiota composition are accompanied by increased intestinal 
permeability that may play a role in the endotoxemia and pro-inflammatory environment 
observed in patients with CKD. Additionally, diminished renal clearance and systemic 
alterations play a major role in the accumulation of gut-derived uremic toxins and 
inflammatory cytokines further exacerbating these phenotypes in patients with CKD 
(Figure 1.2). As compared to other disease states described above, studies are sparse 
as to whether there truly is a functional defect in the intestinal barrier in CKD mouse 
models. It is difficult to determine whether these phenotypes are due to changes in the 
intestinal environment or reduced renal clearance; however, the gut serves as a 





Figure 1.2 Kidney disease results in the accumulation of microbial metabolites 
and endotoxemia. In addition to decreased renal clearance, CKD patients exhibit 
systemic and intestinal changes that results in the accumulation of microbial metabolites 
and endotoxemia.  
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To date, research in CKD has only focused on the composition of the intestinal 
microbiota and expression of intestinal tight junction proteins. Furthermore, studies have 
provided conflicting results as to whether there truly is decreased intestinal tight junction 
protein expression. Contrary to other published reports in CKD models, Anderson et. al. 
observed by electron microscopy that there appears to be no change in intestinal tight-
junction ultrastructure in the Col4a3-/- CKD mouse model (50). Lastly, the mechanism 
leading to intestinal dysbiosis in CKD has not been determined. Urea may be an initial 
driver, but the role of other uremic toxins and LPS, which disrupts tight-junction protein 
expression (61), has yet to be explored.  
To successfully design therapies targeting intestinal environment in CKD 
patients, a full examination of the intestinal microbiota and intestinal barrier is 
warranted. First, technology is to the point where metagenomic and metatranscriptomic 
sequencing of the intestinal microbiota is more easily performed. These types of 
analyses provide valuable information about shifts in the metabolic pathways rather 
than shifts in relative microbial abundance that is the focus of 16S rRNA sequencing. As 
the technology progresses and price decreases, it may become possible to develop 
personalized therapies targeting metabolic pathways altered in each individual patient 
with CKD.  
In regard to the intestinal barrier, studies first determining changes in each 
component of the barrier are warranted. This would include characterizing the 
composition of the mucus layer, determining whether there is diminished AMP 
production, and better characterizing the intestinal immune state in CKD animals. In 
addition to the intestinal barrier and immune system, studies have yet to explore the 
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effect of kidney disease on components of the enteric nervous system, especially as a 
common symptom in CKD patients is diminished gut motility (87,88).  
 In this dissertation, I will highlight my work to: (1) investigate how CKD alters the 
metabolism of trimethylamine N-oxide (TMAO), a novel uremic toxin thought to 
contribute to cardiovascular disease in CKD, and (2) determine if alterations in intestinal 
alkaline phosphatase expression and activity may contribute to impaired intestinal 




Chapter 2: Chronic Kidney Disease Increases Flavin Monooxygenase Activity and 
Circulating Trimethylamine N-Oxide Concentrations in Mice 
 
INTRODUCTION 
Patients with chronic kidney disease (CKD) exhibit a substantial burden of 
cardiovascular disease (CVD) that is disproportionate to that observed in patients with 
comparable comorbidities and normal kidney function (89-91). It is clear that this 
increased burden of CVD in CKD patients is not solely driven by a higher prevalence of 
traditional risk factors for CVD development, such as diabetes and hypertension (4). 
Emerging evidence suggests that a number of metabolic byproducts produced by 
intestinal bacteria may serve as cardiovascular toxins and non-traditional risk factors for 
accelerated CVD progression in CKD (92).  
Through an unbiased metabolomics approach, trimethylamine N-oxide (TMAO) 
and its precursors, L-carnitine and choline, were found to correlate with CVD outcomes 
in patients with normal kidney function. The bacterial metabolism of dietary L-carnitine 
and choline produces the gas trimethylamine (TMA), which is rapidly absorbed into 
systemic circulation and oxidized by the hepatic flavin monooxygenase (FMO) 3 
enzyme. Antibiotic treatment in both rodents and humans resulted in diminished TMAO 
production after choline or L-carnitine challenge, further proving the necessity of the 
microbiota in its production (93,94).  
The direct stimulation of CVD outcomes by TMAO was elucidated in various 
rodent models. Most notably, high serum TMAO levels resulted in increased 
atherosclerotic plaque burden in the ApoE-/- mouse, a model predisposed to 
atherosclerosis development, while antibiotic therapy to lower serum TMAO attenuated 
	 18 
disease progression (93,95). In vitro studies demonstrated that TMAO can also directly 
induce inflammation in vascular endothelial cells (96). In addition to atherosclerosis, 
TMAO is implicated in the development of cardiac fibrosis (97) and platelet hyperactivity 
(98).  
CKD patients exhibit serum TMAO concentrations that far exceed those 
observed in patients with normal kidney function, with serum concentrations often 30 to 
100-fold higher in patients with end-stage renal disease (ESRD) (70,99,100). Existing 
data support that TMAO clearance from the bloodstream occurs primarily through 
urinary excretion (101). However, formal studies investigating the mechanisms 
responsible for TMAO accumulation in CKD are lacking. In the current study, we utilized 
CKD mice to investigate how decreases in kidney function alter both renal excretion and 
hepatic production of TMAO. 
METHODS 
Animal Model and Urine Collection  
 
All mice were maintained in accordance with recommendations in the “Guide for 
Care and Use of Laboratory Animals,” from the Institute on Laboratory Animal 
Resources, National Research Council (National Academy Press, 1996), and all animal 
protocols were reviewed and approved by the University of Kansas Medical Center 
Institutional Animal Care and Use Committee prior to the commencement of this 
research. Kidney disease was induced by feeding C57BL/6J mice that were bred at the 
University of Kansas Medical Center a diet containing 0.2% adenine (Harlan Teklad, 
Madison, WI) starting at 6 weeks of age. Due to differences in kidney disease 
progression between sexes consuming an adenine diet, females were maintained on 
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the diet for 12 weeks, whereas males were provided the diet for 10 weeks (102). At the 
time of sacrifice, mice were placed in metabolic cages to obtain a fasting urine collection 
(12 hours). Prior to this fasting urine collection, mice were housed in the metabolic 
cages eight hours per day for three days for environmental acclimation and provided a 
1% agar diet to promote hydration. At sacrifice, harvested tissue was either fixed for 
histology or snap frozen and stored at -80°C until further processing.  
Serum and Urine Biochemistries 
Serum blood urea nitrogen (BUN) and creatinine was measured using an Integra 
400 plus bioanalyzer (Roche Diagnostics, Indianapolis, IN). Urine creatinine was 
measured by colorimetric assay (Caymen Chemical, Ann Arbor, MI), relying on the Jaffe 
reaction. Serum and urine TMAO was quantified by ultra-performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) as previously reported 
(103). Renal clearance and fractional excretion (FE) of TMAO was calculated using 
Equation 1 and Equation 2, respectively.  






Eq 2: 𝐹𝐸	𝑇𝑀𝐴𝑂	(%) = 100	×
𝑢𝑟𝑖𝑛𝑒	 𝑇𝑀𝐴𝑂 	(µ𝑀)×	𝑠𝑒𝑟𝑢𝑚	 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 (𝑚𝑔𝑑𝐿 )





Kidneys were fixed in 4% PFA for 24 hours and after paraffin embedding, 5 µm 
sections were obtained. Mid-sagittal regions of the kidneys were stained by the period-
acid Schiff (PAS) method (Sigma, St. Louis, MO).  
Assessment of Liver FMO3 Expression and Activity 
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For quantitative real time-PCR assessment of liver FMO3 gene expression, total 
RNA was isolated following homogenization of liver tissue using TRI-Reagent 
(Molecular Research Center, Cincinnati, OH). First strand cDNA was synthesized from 
1 µg RNA using iScript (BioRad, Hercules, CA). PCR reactions contained 40 ng cDNA, 
150 nM of each primer, and 1X iQTM SYBRâ Green Supermix (Bio-Rad, Hercules, CA) 
in 20 µl. The threshold cycle (Ct) of each gene product was normalized to the Ct for 
HPRT and gene expression was calculated using the Pfaffl Method (104). Primer 
sequences used were: FMO3-F:5’- CTCAGGCTGTGACATTGCTG -3’, FMO3-
R:5’CGACTCATCACCCAA GAACC -3’; HPRT-F:5’-
TGATAGATCCATTCCTATGACTGTAGA -3’, HPRT-R:5’AAG 
ACATTCTTTCCAGTTAAAGTTGAG -3’.  
Hepatic FMO activity was assessed by quantifying FMO mediated formation of 
TMAO from TMA in liver microsomes. Microsomes were isolated from frozen liver tissue 
by differential ultra-centrifugation, as previously described with slight modification (105). 
Briefly, mouse livers from the same group were pooled together in sets of three and 
homogenized in ice-cold buffer (50 mM Tris-HCl buffer, 150 mM KCl, 1 mM EDTA, 0.1 
mM dithiothreitol and 20% glycerol, pH 7.4) containing 0.1 mM phenylmethylsulfonyl 
fluoride and 0.113 mM butylated hydroxytoluene as protease inhibitors. The 
homogenate was centrifuged at 20,000g for 30 min at 4°C. The supernatant was then 
centrifuged at 140,000g for 30 min at 4°C. The microsomal pellet was re-suspended in 
0.154 M KCl and was then centrifuged at 140,000g for 30 min at 4°C. The microsomal 
pellet was then finally re-suspended in 20 mM Tris-HCl (pH 7.4) containing 0.25 M 
sucrose. Protein concentrations were determined using a Bio-Rad protein assay (Bio-
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Rad Laboratories, Hercules, CA), and incubations were conducted for each pooled 
group using 0.75 mg/mL of microsomal protein in 20 mM Tris-HCl buffer (pH 7.4) 
containing 5 mM MgCl2 and 1 mM NADPH to assess FMO-mediated conversion of TMA 
to TMAO. Prior to adding the substrates, the microsomal incubations in the presence of 
NADPH were pre-warmed for 3 minutes at 37°C. Reactions were started by the addition 
of 3 μL of various concentrations of trimethylamine-HCl (5, 10, 25, 50, 100, 200, 500, 
1000, 2500, and 10000 μM) and incubated for 60 min at 37°C. Each concentration of 
substrate was conducted in triplicate. The final reaction volume was 300 μL. 
Experimental controls omitting substrate and NADPH were included in each experiment. 
Incubations were stopped by adding 300 μL ice-cold MeOH. Final TMAO concentrations 
were quantified as described above. 
Statistical Analysis  
Comparisons between non-CKD and CKD animals were evaluated by Student’s 
t-test, or Mann-Whitney test for data exhibiting a non-normal distribution. TMAO 
formation rates were used to calculate Michaelis-Menten enzyme kinetic parameters for 
FMO function.	Calculations were performed using Prism 7 (GraphPad Software, San 
Diego, CA) and presented as mean ± SD. Parameters were compared by extra sum-of-
squares F tests. 
RESULTS 
Assessment of kidney function and serum TMAO in CKD and control mice 
Consumption of a 0.2% adenine diet led to substantial kidney injury in both 
female and male mice, as demonstrated by kidney histology revealing tubular injury and 
dilation, along with a marked infiltration of immune cells (Figure 2.1 A). Additionally, 
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CKD mice exhibited elevated serum blood urea nitrogen (BUN) concentrations (Figure 
2.1 B; Females: CKD 117.2 ± 35.3 mg/dL vs non-CKD 26.1 ± 4.9 mg/dL, P<0.001; 
Males: CKD 120.5 ± 32.5 mg/dL vs non-CKD 28.5 ± 3.1 mg/dL, P<0.001). At baseline, 
there was a slight elevation in serum TMAO in female mice compared to male mice 
(Figure 2.1 C; Females 6.9 ± 6.1 µM vs Males 1.0 ± 0.5 µM, P=0.07). Serum TMAO 
concentrations in all CKD mice were considerably elevated compared to non-CKD 
controls (Figure 2.1 C; Females: CKD 29.4 ± 32.1 µM vs non-CKD 6.9 ± 6.1 µM, 
P<0.05; Males: CKD 18.5 ± 13.1 µM vs non-CKD 1.0 ± 0.5 µM, P<0.001). 
Urinary Excretion of TMAO 
There was a sex difference in the renal clearance of TMAO in non-CKD mice 
(Females 90.4 ± 78.1 µL/min vs Males 260.4 ± 134.5 µL/min, P<0.05). In both female 
and male mice, CKD resulted in a substantial decrease in the renal clearance of TMAO 
(Figure 2.2; Females: CKD 5.2 ± 3.8 µL/min vs non-CKD 90.4 ± 78.1 µL/min, P<0.01; 
Males: CKD 10.4 ± 8.1 µL/min vs non-CKD 260.4 ± 134.5 µL/min; P<0.001). In addition 
to decreased renal clearance, there was a decrease in the FE TMAO in both sexes with 
kidney injury (Figure 2.3; Females: CKD 52.5 ± 19.6% vs non-CKD 178.3 ± 157.3%; 
P<0.05; Males: CKD 64.8 ± 21.2% vs Non-CKD 240.9 ± 158.9%, P<0.01).  
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Figure 2.1 Adenine consumption led to impaired kidney function and an increase 
in serum TMAO concentrations. Chronic kidney disease (CKD) was induced by 
consumption of a diet containing 0.2% adenine, as described in the Methods section. 
(A) PAS staining of mid-sagittal kidney sections revealed intense immune infiltration and 
tubular dilation in both female and male CKD mice (scale bar=200 µm, 40x 
magnification) The induction of CKD was accompanied by a rise in (B) serum BUN, and 




Figure 2.2 Kidney damage resulted in decreased renal clearance of TMAO. In both 
female and male CKD mice, there was a substantial decrease in the renal clearance of 





Figure 2.3 Impaired kidney function resulted in a decrease in fractional excretion 
of TMAO. The fractional excretion of TMAO (FE TMAO) in both female and male non-
CKD mice was greater than 100%, suggesting a significant contribution of tubular 
secretion to renal clearance of TMAO in non-CKD animals. FE TMAO in the CKD 




Liver FMO3 Gene Expression and Activity 
Quantitative PCR was performed on liver tissue to assess the impact of CKD on 
hepatic FMO3 gene expression. With chronic kidney injury, there was a 13-fold increase 
in FMO3 gene expression in females (Figure 2.4 A; P<0.01) and an 18-fold increase in 
males (Figure 2.4 A; P<0.001). To validate the functional significance of these gene 
expression changes with those observed in CKD mice, we performed ex vivo studies on 
hepatic FMO activity (Figure 2.4 B). At baseline, wild-type (non-CKD) females exhibited 
significantly higher FMO activity compared to males (Females 1838.0 ± 69.9 
pmol/mg/min vs Males 1238.0 ± 26.0 pmol/mg/min; P<0.001). Similar to our 
observations with FMO3 gene expression, CKD mice exhibited enhanced hepatic FMO 
activity in both sexes (Figure 2.4 B; Females: CKD 2099.0 ± 36.4 pmol/mg/min vs non-
CKD 1838.0 ± 69.9 pmol/mg/min, P<0.001; Males: CKD 2188.0 ± 46.1 pmol/mg/min vs 




Figure 2.4 Increased hepatic FMO3 gene expression and activity in response to 
experimental CKD. (A) Quantitative-PCR analysis revealed an increase in liver FMO3 
gene expression. (B) Ex vivo assessment of hepatic FMO activity from CKD and non-





 Based on data from both human and animal studies, TMAO is independently 
linked to atherosclerosis formation and CVD progression (93-95). Additionally, these 
investigations demonstrated a substantial elevation of circulating TMAO concentrations 
in patients with impaired kidney function; thus, TMAO may be an example of a non-
traditional CVD risk factor that is of particular importance in this setting (70,106). While it 
has been widely speculated that increased increments in circulating TMAO in CKD 
primarily result from decreased urinary clearance of this compound, no formal studies 
have been conducted to rigorously test this hypothesis. Therefore, the current study 
was conducted to test how alterations to both urinary excretion and hepatic formation of 
TMAO may be altered in CKD using translational science approaches in mice.  
Our first notable observation was discrepant serum TMAO concentrations 
between female and male wild-type (non-CKD) mice (Figure 2.1 C). While the difference 
in TMAO concentrations between healthy female and male mice was not statistically 
significant, mean TMAO concentrations were approximately 6-fold higher in the non-
CKD females. Interestingly, female wild-type animals exhibited both decreased renal 
clearance and increased FMO activity compared to wild-type males (Figure 2.4). The 
observed difference in TMAO formation between sexes could be explained by the 
established function of testosterone serving as a negative regulator of FMO3 expression 
(107). As for the apparent sex difference in renal clearance of TMAO, studies evaluating 
tubular transport in rat kidneys have previously demonstrated a decrease in organic 
cation transporter (OCT)-2 expression in female animals (108). Since OCT-1 and OCT-
2 are believed to be the primary regulators of TMAO secretion by tubular epithelial cells 
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(109), it is plausible that decreased renal TMAO clearance in wild-type females is a 
direct result of lower transporter abundance. 
Similar to humans with CKD, mice with adenine-induced CKD exhibit 
substantially elevated circulating concentrations of TMAO. As anticipated, renal 
clearance of TMAO in CKD mice of both sexes is dramatically decreased (Figure 2.2). 
As depicted in Figure 2.3, the FE TMAO in the setting of normal kidney function is well 
above 100%, indicating that tubular secretion plays a predominant role in urinary 
elimination of this compound. Prior studies on tubular transport mechanisms in rats with 
adenine-induced CKD have found a dramatic decrease in tubular expression of both 
OCT-1 and OCT-2 (110), the suspected regulators of TMAO transport by renal tubules. 
Thus, we hypothesize that both a decrease in glomerular filtration and altered tubular 
secretion of TMAO actively contribute to its systemic accumulation in CKD.  
 Perhaps the most noteworthy finding of our current investigation was an increase 
in hepatic FMO3 gene expression and FMO activity in both male and female CKD 
animals compared to non-CKD controls (Figure 2.4). Increased hepatic FMO activity 
has previously been observed in streptozotocin induced diabetes model (111). To our 
knowledge, this is the first description of an upregulation of FMO3 activity in CKD 
models. It is unclear how and why FMO3 function would be altered in the setting of 
impaired kidney function; however, it is possible that this induction of FMO3 function by 
CKD could represent a compensatory mechanism to counteract the negative effects of 
uremia on normal physiological process. To this end, in fish, high concentrations of urea 
are thought to stimulate FMO3 activity leading to increased TMAO concentrations (112). 
Moreover, in the in vitro setting, TMAO has been observed to counteract the protein-
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denaturing effect of urea (113,114). Based on this previously described beneficial 
function of TMAO, it is plausible that increases in urea, or associated uremic toxins, 
may stimulate hepatic FMO3 activity in an effort to counteract some of the detrimental 
effects of uremia. In turn, chronic exposure to high circulating concentrations of TMAO 
may have the unintended secondary outcome of promoting cardiovascular toxicity.  
 While studies support a correlation between circulating TMAO concentrations 
and CVD risk in CKD patients, no studies have confirmed whether lowering TMAO can 
attenuate CVD progression in this population. If future studies suggest clinical benefit of 
lowering TMAO concentrations in CKD patients, then it will be important to develop 
therapeutic strategies to target TMAO production or increase TMAO clearance from the 
circulation. It seems plausible that dietary interventions to lower the ingestion of TMAO 
and its precursors would likely alone be insufficient to dramatically lower the high 
concentrations of TMAO observed in CKD patients. Additionally, in the case of patients 
with ESRD, dialysis appears to offer only a transient lowering, with marginal long-term 
effect, on circulating TMAO (115-117). As with other gut-derived uremic toxins, poor 
TMAO clearance by dialysis is likely related to the broad tissue distribution of many of 
these compounds. As demonstrated in a recent post-hoc analysis from the HEMO study 
(116), increasing dialysis intensity in ESRD patients has little impact on chronic TMAO 
exposure in this population (117).  
 Given that dietary interventions and aggressive dialysis are unlikely to 
substantially lower TMAO concentrations in CKD patients, alternative strategies are 
currently being explored. A recently published investigation suggested that changes in 
the intestinal microbiota in CKD patients results in an increased production of TMAO 
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(118). Thus, one reasonable strategy to lower TMAO in CKD patients could be to 
promote a shift of the “pathogenic” bacterial flora to more symbiotic species with less 
capacity for TMA generation. Unfortunately, existing studies investigating the utility of 
prebiotics or probiotics for supporting the growth of more symbiotic bacterial flora in 
CKD patients have largely yielded disappointing results (119). A more targeted 
approach, inhibiting the specific bacterial enzymes that produce TMA, may be a more 
reasonable strategy. Such targeted therapies are currently undergoing testing in 
animals (120). Lastly, the results of our current study would support a need for further 
examination of therapies targeting hepatic FMO activity as an added approach for 
lowering TMAO concentrations in this population. 
 As with any study, the current investigation has both important strengths and 
limitations. Important strengths of our investigation include: use of a precise and 
extensively validated method for TMAO quantification, the inclusion of studies to assess 
hepatic FMO enzyme function, consideration of the impact of gender on the outcomes 
of interest, performing metabolic studies which included timed urine collections for the 
assessment of urinary TMAO excretion, and an overall study design that allows for the 
exclusion of potential confounders that are commonly encountered in human studies 
(i.e. dietary influences, genetic variability, and the presence of disease comorbidities). 
Important limitations of our work include: possible differences between human and 
mouse biology, lack of investigation into specific mechanisms driving the observed 
alterations in hepatic generation or renal clearance of TMAO, no assessment of FMO3 
and FMO1 protein expression, and no assessment of how alterations to the intestinal 
microbiome may have altered TMA formation rates in CKD mice.  
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 In summary, our observations in CKD mice suggest that both a decrease in renal 
clearance of TMAO and an increase in hepatic production of TMAO due to enhanced 
FMO3 activity may equally contribute to TMAO accumulation in CKD. If future studies 
confirm our findings in humans, it will be important to further explore the significance of 
enhanced TMAO formation in CKD and better understand how blockade of FMO3 
activity may alter clinical outcomes in this setting.  
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CHAPTER 3: Intestinal Alkaline Phosphatase (IAP) and Tissue Non-Specific 
Alkaline Phosphatase (TNAP) Activity and Expression in Mouse Models of 
Chronic Kidney Disease 
	
INTRODUCTION 
In patients with CKD, systemic inflammation contributes to the presence of 
numerous comorbid conditions, including CVD, malnutrition, anemia, and mineral-bone 
defects (121). As described in Chapter 1, intestinal barrier defects resulting in the 
translocation of bacteria into the systemic circulation are hypothesized to contribute to 
the pro-inflammatory phenotype observed in CKD patients. Accumulating evidence 
supports a role of alkaline phosphatases in regulating the relative abundance of 
intestinal bacteria and maintaining intestinal barrier function to limit the activation of pro-
inflammatory pathways; however, the contribution of these alkaline phosphatases to gut 
barrier function and inflammation in CKD has yet to be examined.   
	 Alkaline phosphatases (ALP) are a family of GPI-linked metalloenzymes with 
phosphatase activity occurring in the extracellular space, and optimal protein activity 
occurring in alkaline environments. Despite a historical lack of understanding of the 
physiological role of ALP, physicians and scientists have been measuring ALP enzyme 
activity since the 1970s, when clinical studies first reported altered activity levels in 
patients with hepatobiliary disease and skeletal defects (122).  
The isoforms of ALP expressed in the mouse include tissue non-specific alkaline 
phosphatase (TNAP), intestinal alkaline phosphatase (IAP), and embryonic alkaline 
phosphatase (Table 3.1). TNAP (Akp2) is expressed in the liver, kidney, and bone. In 
the liver, TNAP expression and activity is restricted to portal arteries and bile canaliculi 
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(123). Two ALP isoforms expressed in the intestine include Akp3, which is restricted to 
the duodenum, and Akp6, which is expressed globally throughout the small intestine. 
The highest expression of placental-like alkaline phosphatase (Akp5) occurs in the 
placenta, but has also been found in the serum (124), and ectopic expression is used as 
a marker of cancer in the reproductive organs (125,126). Chemical inhibitors are often 
employed to discern differences in isoform activity. For example, levamisole is used as 
an inhibitor of TNAP activity and L-phenylalanine is a potent inhibitor of both IAP (Akp3) 
and placental-like alkaline phosphatase (Akp5) activity (127).  
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Table 3.1 Mouse Alkaline Phosphatase Isoforms.  
Protein Name Gene Name Chemical Inhibitors 
Tissue Non-Specific Alkaline 
Phosphatase (TNAP) 
Akp2 (Liver/Kidney/Bone) Levamisole 
Intestinal Alkaline 
Phosphatase (IAP) 
Akp3 (Duodenum) and 








The role of TNAP in regulating bone and soft tissue calcification through the 
dephosphorylation of pyrophosphate has been established for decades (128); however, 
until recently, the natural substrates for ALP isoforms expressed in the kidney, intestine 
and liver have remained unknown. Due to its anionic nature, researchers speculated the 
bacterial endotoxin LPS may be an endogenous substrate of ALP. The negative charge 
of LPS would sequester free protons increasing the local pH allowing for optimal ALP 
activity, while the phosphates on the sugar residues of the lipid A motif are essential for 
LPS to bind to its receptor and trigger an inflammatory cascade can be removed by ALP 
(129). To investigate the role of ALP in detoxifying LPS, Polestra et. al. injected mice 
with sub-lethal doses of E. coli with and without levamisole, a non-specific inhibitor of 
ALP activity. Mice injected with E. coli and levamisole had a significant reduction in 
survival compared to mice injected with E. coli alone. In addition to this survival study, 
the authors utilized histochemistry techniques to elucidate that the duodenum and liver 
were capable of dephosphorylating LPS at a neutral pH, whereas using a phosphate 
substrate such as b-glycerophosphate, which lacks negative charge, required the 
reaction to occur at a basic pH between 9-10 (129). 
Subsequent studies validated that IAP expression specifically was capable of 
enhancing the survival of rodents injected IP with E. coli or zebrafish exposed to LPS in 
tank water (130,131). In addition to LPS, IAP is capable of dephosphorylating nucleotide 
triphosphates ATP and UTP, bacterial DNA, and modifying the structure of flagella to 
limit the ability of these metabolites to stimulate an inflammatory response (132).  
Deletion of Akp3 in mice resulted in no gross abnormalities of the duodenum and 
ileum (133). Upon further investigation, Akp3-/- mice do display signs of low-grade 
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inflammation, including increased hepatic MHC II staining (134), increased serum 
endotoxin, and increased serum TNFa (135). It is plausible that this inflammatory 
phenotype is driven by subtle changes to the intestinal barrier, as upon oral-LPS 
challenge, more LPS translocates into the systemic circulation of the Akp3-/- mice 
compared to their wild-type counterparts (135). Lastly, there is a shift in the relative 
abundance of the resident bacterial phyla in the stool collected from Akp3-/- mice 
(136,137), possibly due to a local accumulation of ATP that results in limited bacterial 
growth (138). These data suggest a role of IAP in fortifying the intestinal barrier and 
maintaining the relative abundance of intestinal microbe populations; however, studies 
dissecting the mechanism for these proposed roles have yet to be conducted.  
 The activity of IAP is decreased in an array of diseases, including those with 
intense intestinal inflammation, such as inflammatory bowel disease (139), celiac 
disease (140) and cystic fibrosis (141), to chronic diseases exhibiting more subtle 
defects in intestinal barrier function, such as diabetes (142) and alcoholic-liver disease 
(143). Moreover, oral administration of IAP to animal models of metabolic endotoxemia 
(135), alcohol-induced liver injury (144), and cystic fibrosis (141), appears to limit 
inflammation and attenuate disease progression. 
Based on the above observations suggesting a critical function of IAP in the 
preservation of gut barrier function and microbiota composition, we hypothesized that 
CKD would be accompanied by decreased IAP activity, resulting in impaired intestinal 
barrier function in this setting. Furthermore, we speculated that IAP therapy would 
attenuate the inflammatory phenotype observed in CKD. Outside of researchers 
studying the role of ALP in bone and soft tissue calcification, the tissue expression 
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patterns and activity of various ALP isoforms have yet to be explored in CKD models. 
The primary purpose of the studies outlined in this chapter was to characterize the 
expression patterns of ALP isoforms in: (1) the duodenum (due to the high expression 
of IAP at this site), (2) in stool collected from the ileum (to determine whether IAP 
protein may be secreted into the intestinal lumen), and (3) the liver (a major site of LPS 
detoxification). 
METHODS 
Animal Model  
We utilized two CKD mouse models throughout this study. First, readouts 
described below were explored in the collagen 4a3 (Col4a3) knockout model on the 
SVJ/129 background. The Col4a3-/- mice are a model of the human Alport disease, 
while Col4a3+/+ littermates served as non-CKD controls. We validated results observed 
in the Col4a3 model with an adenine-induced model of CKD. Briefly, C57BL6/J mice 
starting at 6 weeks of age were fed a diet containing 0.2% adenine for 12 weeks, and 
mice maintained on an identical diet lacking adenine supplementation served as non-
CKD controls. Non-CKD and CKD mice were housed in separate cages throughout the 
duration of these studies. At the time of sacrifice, tissue was either fixed in 4% PFA or 
snap frozen and stored at -80°C for further analysis.  
Quantitative PCR 
Total RNA was isolated from tissue homogenized with Tri-Reagent (Molecular 
Research Center, Cincinnati, OH) following manufacturer’s protocol. First-strand cDNA 
was synthetized from 1 µg of RNA using iScript (Biorad, Hercules, CA). Quantitative 
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PCR was performed using 1X iQTM SYBRâ Green Supermix (Biorad, Hercules, CA), 
contained 40 ng cDNA, and 150 nM of each primer in 20 µl final volume. Quantification 
was calculated using the Pfaffl method (104), and the threshold cycle (Ct) of each gene 
product was normalized to the Ct for HPRT. Primer sequences used were: LBP F-
CCACAGATGGAGATCGAAGG and R-TGAGGCAAATACATTAGTGACCA; CD14 F-
AAAGAAACTGAAGCCTTTCTCG and R-AGCAACAAGCCAAGCACAC; IL1b F- 
GCCACCTTTTGACAGTGATGAG and R-GACAGCCCAGGTCAAAGGTT; TLR4 F-
CGCTTTCACCTCTGCCTTCACTACAG and R-ACACTACCACAATAACCTTCCGGG 
TC; Akp3 F-CATGGACCGCTTCCCATA and R-CTTGCACTGTCTGGAACCTG; Akp6 
F-GGACCCAGCAGTAACTCACC and R-TGGTCAATACGACCCCCTTC; TNAP F-
CCTGACTGACCCTTCGCTCT and R-CTGCTTGGCCTTACCCTCAT; HPRT F-
TGATAGATCCATTCCTATGACTGTAGA and R-AAGACATTCTTTCCAGTTAAAG 
TTGAG. 
Alkaline Phosphatase Activity 
Alkaline phosphatase (ALP) activity was measured by fluorometric assay using 
4-methylumbelliferyl phosphate disodium salt as a phosphate substrate (Abcam, 
Cambridge, UK). Following manufacturer’s protocol, tissue was homogenized and 
diluted using provided lysis buffer. To discern IAP activity from other possible ALP 
sources, samples were run in parallel with and without 10 mM L-phenylalanine, an 
inhibitor of IAP activity. The L-phenylalanine sensitive IAP activity was calculated by 
subtracting the activity value obtained in wells with L-phenylalanine from those without 
L-phenylalanine. In intestinal tissue, this L-phenylalanine sensitive activity will be 
labeled IAP activity whereas in the liver, bone and serum, this activity will be labeled as 
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L-phenylalanine sensitive ALP activity, since IAP is not expressed by these sources. 
Protein activity was normalized to the total protein content of the sample, determined by 
BCA assay (Pierce, Rockford, IL). 
Immunoblotting   
Tissue used for immunoblotting was previously lysed for the ALP activity assay 
described above. Between 30 and 100 µg of protein was diluted in NuPAGE® reducing 
buffer (Life Technologies, Carlsbad, CA), incubated at 70°C for 10 minutes, and 
resolved on 4-12% Bis-Tris gels (Life Technologies, Carlsbad, CA). Proteins were 
transferred onto PVDF membrane using semi-dry transfer. Membranes were stained 
with Ponceau S, blocked in 5% milk, and then incubated with either primary IAP 
(Abcam, Cambridge, UK; ab97532) or TNAP (Abcam, Cambridge, UK; ab108337) 
antibodies overnight. Blots were incubated with HRP-conjugated secondary antibodies 
and Enhanced Chemiluminescent substrate was used to generate luminescence (GE 
Healthcare, Piscataway, NJ). Blots were visualized using GE Amersham Imager 600 
(GE Healthcare, Piscataway, NJ), and densitometry analysis was performed using 
Image J software (National Institute of Health, USA). Protein quantification was 
normalized to total protein content after Ponceau S staining of the membrane.  
IAP Immunohistochemistry 
Tissues were fixed in 4% PFA for 24 hours, paraffin embedded, then cut into 5 
µm sections. After deparaffinization, heat-mediated antigen retrieval using citrate buffer 
(Sigma, St. Louis, MO) at pH 6.0 was performed. Endogenous peroxidase activity was 
quenched with 3% H202, then tissue sections were blocked and incubated with the IAP 
primary antibody overnight at 4°C. Sections were washed and incubated with HRP-
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conjugated secondary antibody (ImmPRESS, Vector Laboratories, Burlingame, CA) and 
visualized using Diaminobenzidine (ImmPACT, Vector Laboratories, Burlingame, CA). 
Statistical Analysis 
Comparisons between non-CKD and CKD animals were evaluated by Student’s 
t-test, or Mann-Whitney test for data exhibiting a non-normal distribution.	Calculations 
were performed using Prism 7 (GraphPad Software, San Diago, CA) and presented as 
mean ± SD.  
RESULTS 
Inflammatory phenotype of the liver and spleen in CKD mice 
To first assess a possible inflammatory phenotype originating from intestinal 
barrier dysfunction, we performed gene expression analysis of LPS signaling proteins 
(LBP, CD14, and TLR4) and the inflammatory cytokine IL1b. Luminal content of the 
digestive tract is absorbed into systemic circulation either through the portal vein or the 
lymphatic system; therefore, we performed qPCR analysis on the livers and spleens 
collected from non-CKD (Col4a3+/+) and CKD (Col4a3-/-) mice. Kidney disease resulted 
in a 3.5-fold increase in liver gene expression of LBP (Figure 3.1A, P<0.05), a 2-fold 
increase in CD14 (Figure 3.1B, P<0.05), and a trend toward increased IL1b gene 
expression (Figure 3.1 C; P=0.09). Within the spleen, we observed a significant 
increase in IL1b (Figure 3.1 D; P<0.05) and TLR4 gene expression (Figure 3.1 E; 




Figure 3.1 Quantitative-PCR analyses of inflammatory markers in the (A-C) liver 
and (D and E) spleen of Col4a3+/+ (non-CKD) and Col4a3-/- (CKD) mice. Kidney 
disease resulted in a significant increase in liver (A) LBP and (B) CD14 gene 
expression. A slight elevation in (C) IL1b was observed in the livers of CKD mice. 
Additionally, there was a significant increase in the gene expression of (D) IL1b and (E) 
TLR4 in the spleens of CKD mice. *P<0.05 vs non-CKD controls 
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Small intestine IAP activity and expression in CKD mice 
In the Col4a3 model, there was a 50% reduction in duodenum IAP activity in 
CKD mice compared to non-CKD controls (Figure 3.2 A; CKD 311,353 mU/mg protein 
vs non-CKD 610,074 mU/mg protein, P<0.05). In the adenine-induced model of CKD, a 
substantial reduction of duodenum IAP activity was also observed (Figure 3.2 B; CKD 
208,709 mU/mg protein vs non-CDK 559,826 mU/mg protein, P=0.11). Further analysis 
of duodenum collected from Col4a3+/+ and Col4a3-/- revealed no change in the gene 
expression of IAP isoforms expressed in the duodenum, Akp3 and Akp6 (Figure 3.2 C 
and D). To determine the reactivity of our IAP antibody, we immunoblotted duodenum 
tissue of Akp3+/+ and Akp3-/- mice and no staining occurred in the Akp3-/- mice. No 
change in duodenum IAP protein expression occurred with the induction of CKD (Figure 
3.2 G and F). Furthermore, immunohistochemistry for IAP in non-CKD mice revealed 
diffuse cytoplasmic staining that was lost in the duodenum of CKD mice (Figure 3.3 A). 
Under low magnification of the duodenum, IAP protein staining appeared to be shed 




Figure 3.2 Duodenum IAP activity, gene and protein analysis. (A) Within the 
duodenum of Col4a3-/- (CKD) mice, there was a significant decrease in IAP protein 
activity compared to Col4a3+/+ mice (non-CKD). (B) This same trend was observed in 
mice maintained on a diet containing adenine for 12 weeks to induce kidney injury 
(P=0.11). There were no changes in gene expression of the duodenum IAP isoforms, 
(C) Akp3 and (D) Akp6. (G, F) Immunoblot analysis and quantification for IAP protein 
expression proved there to be no difference in whole-tissue lysate protein expression of 




Figure 3.3 Cellular localization of duodenum IAP in Col4a3+/+ (non-CKD) and 
Col4a3-/- (CKD) mice. (A) In the duodenum of non-CKD mice, IAP protein expression is 
predominantly localized to the apical membrane, with diffuse cytoplasmic staining. CKD 
mice, while still having IAP staining at the apical membrane, was void of cytoplasmic 
staining. (scale bar=100 µM, 200X magnification). (B) Low power images demonstrated 
IAP staining in the intestinal lumen of CKD mice (20X magnification).  
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To explore the possibility of IAP protein being secreted from the duodenum, and 
retained within the stool, we examined IAP activity and protein expression of luminal 
content collected from a downstream intestinal segment, the ileum. We observed an 
approximate 2-fold increase in both IAP activity (Figure 3.4 A; CKD 9,371,407 mU/mg 
protein vs non-CKD 4,983,876 mU/mg protein, P=0.07) and protein expression (Figure 
3.4 B and C; P=0.4). Additionally, there was an approximate 2-fold increase in IAP 
activity in ileum tissue cleaned of stool (Figure 3.5; CKD 164,535 mU/mg protein vs 




Figure 3.4 IAP activity within stool collected from the ileum of Col4a3+/+ (non-
CKD) and Col4a3-/- (CKD) mice. (A) In CKD mice, increased IAP activity in stool 
obtained from the ileum of mice (P=0.07). (B, C) The rise in activity was accompanied 




Figure 3.5 Ileum tissue activity in Col4a3+/+ (non-CKD) and Col4a3-/- (CKD) mice. 
There was a modest increase in IAP activity in ileums collected from CKD compared to 
non-CKD mice P=0.28.  
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Hepatic ALP activity and expression in CKD mice 
 In the Col4a3 model, there was a significant increase in hepatic TNAP (Figure 
3.6 A; CKD 3,140 mU/mg protein vs non-CKD 294.1 mU/mg protein, P<0.001) and L-
phenylalanine sensitive ALP activity in CKD mice (Figure 3.5 B; CKD 260.3 mU/mg 
protein vs non-CKD 54.7 mU/mg protein, P<0.001). These results were corroborated in 
the adenine-induced CKD mouse model for hepatic TNAP (Figure 3.6 C; CKD 18,017 
mU/mg protein vs non-CKD 1,622 mU/mg protein; P<0.01) and L-phenylalanine 
sensitive ALP (Figure 3.6 D; CKD 2,418 mU/mg protein vs non-CKD 129.5 mU/mg 
protein; P<0.05) activity. Kidney injury resulted in no change in liver TNAP gene 
expression in Col4a3-/- mice (Figure 3.7 A), however, there was a 50% increase in 
TNAP protein expression (Figure 3.7 B and C, P<0.05). Immunoblotting liver lysate with 
the IAP antibody revealed two bands at a molecular weight near 150 kDa that was also 
observed in liver tissue from Akp3-/- mice (Figure 3.8 A), possibly suggesting detection 
of an alternate ALP isoform. Additionally, there was an increase in liver staining with the 
IAP antibody in both the Col4a3 model (Figure 3.8 B) and the adenine-induced model of 
CKD (Figure 3.8 C).   
Systemic ALP Activity 
To determine whether the changes to ALP activity were occurring systematically 
or restricted to the gut-liver axis of CKD mice, we measured ALP activity in the bone 
and serum of CKD animals. No change in TNAP and L-phenylalanine sensitive ALP 
activity was observed in the bone (Figure 3.9 A and B) or serum (Figure 3.9 C and D) of 




Figure 3.6 Liver ALP activity. In the Col4a3-/- (CKD) mice, there is a significant 
increase in liver (A) TNAP and (B) L-phenylalanine sensitive ALP activity compared to 
Col4a3+/+ (non-CKD) mice. Furthermore, in an adenine-induced CKD model, this finding 
of increased liver (C) TNAP and (D) L-phenylalanine sensitive ALP activity is replicated. 





Figure 3.7 Hepatic TNAP gene and protein expression in Col4a3+/+ (non-CKD) and 
Col4a3-/- (CKD) mice. (A) Hepatic TNAP gene expression was unchanged in the livers 
of CKD mice compared to non-CKD mice. (B, C) Immunoblot analysis of livers revealed 
a slight and significant increase in TNAP protein expression in CKD mice compared to 




Figure 3.8 Protein analysis of livers with IAP antibody. (A) Immunoblot analysis of 
livers from Col4a3+/+ (non-CKD) and Col4a3-/- (CKD) for IAP protein expression. Two 
bands appeared at a molecular weight of 150 kDa. These same bands appeared in liver 
tissue collected from the Akp3-/-. Through immunohistochemistry staining of the liver 
with the IAP antibody, the (B) Col4a3 model of CKD and (C) adenine-induced model of 





Figure 3.9 TNAP and IAP activity in bone and circulation of Col4a3+/+ (non-CKD) 
and Col4a3-/- (CKD) mice. Within the calvaria, there was no difference in (A) TNAP and 
(B) L-phenylalanine sensitive ALP activity. Likewise, there was no observed difference 
in serum (C) ALP and (D) L-phenylalanine sensitive ALP activity.  
	 54 
DISCUSSION 
	 IAP and TNAP activity are implicated in maintaining intestinal barrier function and 
limiting systemic inflammation. Moreover, decreased IAP activity is observed in disease 
states characterized by a pro-inflammatory phenotype and IAP therapy attenuates 
systemic inflammation. CKD patients exhibit evidence of intestinal barrier dysfunction 
that likely contributes to a pro-inflammatory phenotype; however, the role of IAP in 
CKD-related barrier dysfunction has yet to be explored. The current study was designed 
to characterize the expression and activity of IAP in the intestine, and hepatic ALP 
expression and activity, as the liver is a major site of detoxification of LPS and other 
bacterial byproducts.  
  Our first notable observation in this study is a decrease in duodenum IAP activity 
in CKD (Col4a3-/-) mice compared to non-CKD controls (Col4a3+/+) (Figure 3.2 A); this 
trend of decreased duodenum IAP activity was confirmed in an alternative CKD model 
(adenine diet) (Figure 3.2 B). Furthermore, decreased IAP activity in CKD mice is not 
due to decreased gene or protein expression, instead suggesting altered post-
translation modification of the IAP protein, altered cellular localization, or the presence 
of a factor capable of modifying the enzymatic activity of IAP. Interestingly, unlike TNAP 
activity, IAP activity is not dependent on its glycosylation state (145); therefore, our 
finding of a loss of cytoplasmic expression within duodenal enterocytes of CKD mice 
would suggest this loss of IAP activity is accompanied by a major shift in the cellular 
localization of IAP expression. (Figure 3.3). A possible mechanism responsible for this 
phenomenon could be altered expression of bacterial phospholipases capable of 
cleaving the GPI-anchor of the IAP protein. In turn, cleaved protein may get trapped in 
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the mucus layer of the duodenum and lose its enzymatic activity, or maintain its activity 
and travel downstream into stool from distal intestinal segments, such as the ileum 
(Figure 3.4). An alternative mechanism resulting in increased activity and protein 
expression we observed within the stool is the production of IAP by the ileum. In support 
of this scenario, we do observe a modest increase in IAP activity in CKD mouse ileum 
that has been washed of fecal contents (Figure 3.5). 
 Most convincingly, we have shown that both TNAP and an ALP isoform sensitive 
to L-phenylalanine inhibition are increased in the livers of Col4a3 and adenine-induced 
CKD mouse models (Figure 3.5). Increased activity was accompanied by increased 
whole-tissue protein levels of TNAP, and increased IHC staining with an IAP antibody 
that may be due to increased placental-like ALP expression. A similar phenotype of 
increased hepatic ALP activity is observed in other inflammatory diseases including 
hepatic diseases (146,147), cystic fibrosis (148), and E. coli induced bacteremia in 
humans (149).  
 Interestingly, the significant increase in hepatic ALP activity in CKD mice was not 
reflected in overall serum phosphatase activity. This may be due to liver ALP only being 
a minor source of circulating phosphatase activity in mice (123). Consistently, CKD 
patients do not regularly exhibit increased serum ALP activity, except in the setting of 
concomitant high bone turnover states (150). An alternative explanation for this 
observation may be a lack of liver ALP solubility upon kidney injury. An analogous 
scenario was described in rats undergoing hepatectomy compared to rats undergoing 
bile duct ligation. In both scenarios, increased liver ALP activity at the tissue level was 
observed, but a change in circulating ALP activity was only present in the animals 
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undergoing bile duct ligation. The authors of this investigation went on to speculate a 
role of bile acids in solubilizing liver ALP for its release into the bloodstream (151).    
 While we provide data that IAP and TNAP activity is altered in the gut-liver axis of 
CKD mice, we are unsure of the clinical significance of these finding and mechanisms 
regulating intestinal and liver ALP activity. To address these gaps in our knowledge, we 
have first designed studies examining the impact of kidney injury in the Akp3-/- mice, to 
determine whether the loss of Akp3 exacerbates the pro-inflammatory phenotype 
observed in CKD mice. Additionally, we have designed experiments to determine 
whether IAP therapy can reduce inflammation in CKD mice. In separate studies, we 
plan to determine the significance of increased hepatic ALP activity in CKD mice by 
determining the effect of inhibition of enzyme activity on pro-inflammatory pathways and 
endotoxemia. ALP inhibition will be accomplished using a novel TNAP inhibitor, SBI-425 
(152). We hypothesize that the upregulation of liver ALP in CKD is a compensatory 
mechanism to limit inflammation driven by increased entry of bacterial endotoxins into 
the portal circulation when gut barrier function is compromised; therefore, we anticipate 
that inhibition of ALP activity in the setting of CKD would intensify the pro-inflammatory 
phenotype. Regulation of ALP activity will be further explored in Chapter 4 of this 
dissertation.  
 This study has both strengths and weaknesses. Strengths of these studies 
include: the use of two separate CKD models to validate important observations, the 
use of Akp3-/- tissue to validate the specificity of our antibody, and ALP activity data 
being interpreted in conjunction with expression data. Weaknesses of this study include: 
not knowing what isoform our antibody is reacting with in the liver, the lack of TNAP IHC 
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staining within the liver, and overall ALP activity staining within the liver to determine if 
hepatic IHC staining localizes with the actual phosphatase activity.   
 In summary, our studies provide evidence that decreased IAP activity in CKD 
animals may be a contributing factor to altered intestinal biology observed after kidney 
injury. It is now important to explore the clinical significance of the changes in activity 
patterns, and whether IAP therapy can attenuate the inflammatory phenotype observed 
in CKD.  
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	 Despite extensive research characterizing intestinal alkaline phosphatase (IAP) 
activity in disease states accompanied by intestinal barrier defects, studies exploring the 
mechanisms regulating IAP activity and expression are sparse. The majority of existing 
data does support some role of intestinal microbes in regulating IAP expression. For 
example, in both germ-free zebrafish and germ-free mice, IAP activity or gene 
expression is diminished (130,153). Furthermore, oral administration of the bacterial 
endotoxin, LPS, stimulates intestinal ALP activity within 2 hours of administration; 
however, this activity resolves within 6 hours (154) possibly due the production of 
inflammatory cytokines IL1b and TNFa, as these cytokines reduce IAP activity in vitro 
(155). Moreover, fasting animals demonstrate significantly lower duodenum IAP activity, 
with refeeding resulting in a rescue of this phenotype (156). Finally, unpublished 
observations from our lab suggest that co-housing CKD mice with non-CKD littermates 
results in a preservation of duodenal IAP activity in CKD animals. Taken together, these 
studies all suggest a potential role of the intestinal microbiota in regulating duodenum 
IAP activity.  
 Regulation of hepatic ALP activity is mostly studied in the context of liver 
disease, with little knowledge of ALP activity changes in other disease states. With liver 
injury, it is hypothesized that translocation of bacterial endotoxins from the gut lumen 
into portal circulation stimulates liver ALP activity. Furthermore, intraperitoneal LPS 
injection into wild-type mice results in increased hepatic TNAP gene expression (157); 
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however, ALP activity was not reported in these studies. Alternatively, bile acids are 
known to induce ALP activity in cultured rat hepatocytes (158), and biliary obstruction 
leads to a dramatic increase in hepatic ALP activity; yet, it is still unclear if bile acids are 
a direct in vivo regulator of hepatic ALP activity. 
We hypothesized that alterations to the intestinal lumen contents (i.e. relative 
microbiota content or bile acid composition) in CKD result in decreased duodenum IAP 
activity, and a compensatory increase liver ALP enzymatic activity. To test this 
hypothesis, we performed fecal transplant studies to determine if stool from Col4a3+/+ 
(non-CKD) and Col4a3-/- (CKD) mice could alter intestinal and hepatic ALP activity in 
wild-type recipients. Additionally, we injected wild-type mice with LPS to determine 
whether this bacterial byproduct alone can stimulate liver ALP activity. 
METHODS 
Fecal Transplant Study Design 
Cecal content was collected from Col4a3+/+ and Col4a3-/- mice at the time of 
sacrifice and snap frozen for later use. Cecal stool samples from three mice of the same 
genotype were pooled (i.e. 3 male Col4a3+/+ were combined and 3 male Col4a3-/- were 
combined) and diluted 1:10 by weight in PBS + 50% glycerol to form the non-CKD and 
CKD fecal treatments. Immunoblot analyses of these samples were performed to 
determine whether any IAP protein was present in the supernatant.  
As depicted in Figure 4.1, prior to fecal transplant, male C57BL/6J mice were 
administered an antibiotic cocktail (1 g/L ampicillin, 1 g/L neomycin, 1 g/L 
metronidazole, and 0.5 g/L vancomycin) through their drinking water for 2 weeks. At the 
end of this 2-week period, mice were randomized to receive either 150 µL of non-CKD 
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or CKD cecal content for a 3-week period. Prior to gavage, processed cecal stool 
samples were further diluted 1:5 in PBS. Oral gavage of fecal content was performed 3 
times the first week (MWF), then once per week for the final 2 weeks (M). At the time of 
sacrifice, blood and tissue were collected and either fixed in 4% PFA or snap frozen and 
stored at -80°C.   
Intraperitoneal LPS Injection 
Wild-type C57Bl/6J mice were I.P. injected with 2 mg/kg of LPS (E. coli) or 
vehicle. Mice were sacrificed 6 hours after injection and tissue was snap-frozen and 
stored at -80°C for further analysis. 
Tissue Analysis 
 All methods for kidney histology were described in detail in Chapter 2, whereas 
methods for qRT-PCR, alkaline phosphatase activity, immunoblotting, and 




Figure 4.1 Fecal transplant study design. Male C57BL/6J mice at 10 weeks of age 
were administered an antibiotic cocktail containing 1 g/L ampicillin, 1 g/L neomycin, 1 
g/L metronidazole, and 0.5 g/L vancomycin for 2 weeks. After 2 weeks, mice were 
randomized to receive processed cecal contents from previously sacrificed non-CKD or 
CKD mice. Mice were administered the fecal slurry by oral gavage three times during 
the first week of treatment, then once weekly for the final two weeks. After 5 weeks, the 





IAP Expression in Cecal Content and Kidney Histology  
There was no detectable IAP protein expression in the non-CKD and CKD fecal 
slurry (Figure 4.2 A). Additionally, there was no sign of kidney damage in the recipient 
mice (Figure 4.2 B).  
IAP Protein Activity and Expression in the Small Intestine 
Fecal transplant of CKD stool resulted in no change in IAP activity within the 
duodenum or stool content of the ileum compared to wild-type mice receiving non-CKD 
stool (Figure 4.3 A and B). There was a 7-fold increase in duodenum IAP protein 
expression in wild-type mice receiving CKD stool (Figure 4.3 C and D, P<0.05). IAP 
immunohistochemistry staining revealed that mice receiving non-CKD stool 
demonstrated strong staining at the apical membrane along with diffuse cytoplasmic 
staining of enterocytes, which is similar to the baseline staining patterns observed in 
non-CKD mice described in Chapter 3. In contrast, duodenal sections from the mice 
receiving CKD stool demonstrated apical membrane staining of enterocytes that was 
comparable to mice receiving non-CKD stool; however, cytoplasmic staining of 




Figure 4.2 IAP expression in fecal content and kidney histology. (A) Immunoblot 
analysis revealed no detectable IAP expression in the cecal content pooled from non-
CKD and CKD mice. (B) Fecal transplant did not result in overt kidney damage\ as 





Figure 4.3 Intestinal IAP activity and expression.	There was no difference in IAP 
activity in the (A) duodenum or (B) stool collected from the ileum of wild-type mice 
receiving CKD stool compared to those that received non-CKD stool. (C, D) There was 
a significant increase in IAP protein expression in mice receiving CKD stool. (E) 
Immunohistochemistry staining for IAP revealed more diffuse cytoplasmic staining in the 
mice receiving CKD stool versus those receiving non-CKD stool (scale bar = 100 µm, 
200X magnification). *P<0.05 vs non-CKD stool controls 
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Liver ALP Activity and Expression 
Fecal transplant of CKD stool into wild-type mice did not elicit an inflammatory 
phenotype in the liver, as we previously observed in our CKD animals (Chapter 3). 
Briefly, comparing wild-type mice receiving CKD stool versus non-CKD stool, there was 
no difference in hepatic gene expression for LBP, CD14, TLR4, or IL1b (Figure 4.4). On 
the other hand, we did observe a dramatic increase in liver TNAP activity (Figure 4.5 A, 
CKD stool 5,104 mU/mg protein vs non-CKD stool 863.4 mU/mg protein, P<0.05) and L-
phenylalanine sensitive ALP activity (Figure 4.5 B, CKD stool 1,686 mU/mg protein vs 
non-CKD stool 161 mU/mg protein, P<0.05) in mice receiving CKD stool. Furthermore, 
mice receiving CKD stool had a 2-fold increase in hepatic gene expression of TNAP 
(Figure 4.6, P=0.06). Immunohistochemistry using an IAP antibody revealed increased 
hepatocyte staining around portal triads and central veins in mice receiving CKD stool 
versus non-CKD stool (Figure 4.7 A). Mice receiving non-CKD stool had largely 
hepatocyte nuclear staining, along with a distinct pattern of staining around the portal 
triads (Figure 4.7 B). Lastly, I.P. injection of LPS into wild-type mice resulted in reduced 
liver TNAP activity (Figure 4.8, LPS 1,202 mU/mg protein vs vehicle 1,908 mU/mg 





Figure 4.4 Quantitative-PCR analyses of inflammatory markers in the liver. 
Comparing wild-type mice that received CKD stool to those that received non-CKD 
stool, there was no change in hepatic gene expression of (A) LBP, (B) CD14, (C) TLR4, 




Figure 4.5 Liver ALP activity after fecal transplant. There was an increase in liver 
(A) TNAP and (B) L-phenylalanine sensitive ALP activity in wild-type mice receiving 





Figure 4.6 Hepatic TNAP gene expression after fecal transplant. There was an 
increase in TNAP gene expression in mice receiving CKD stool compared to those that 





Figure 4.7 Liver immunohistochemistry staining with IAP antibody. (A) We 
observed increased IAP staining in livers of wild-type mice that received CKD stool 
compared to those that received non-CKD stool (scale bar = 100 µm, 40X 
magnification). (B) Under higher magnification, there was nuclear staining (arrows) and 
a distinct staining pattern around the portal triads in the livers of mice that received non-
CKD stool. On the other hand, mice that received CKD stool demonstrated 
predominantly cytoplasmic IAP staining of hepatocytes around portal triads and central 




Figure 4.8 Liver ALP activity after LPS injection. There was a decrease in ALP 







Defects in intestinal ALP activity are implicated in the pathophysiology of several 
diseases characterized by intestinal barrier defects, while alterations to liver ALP activity 
are well-documented in a number of hepatobiliary diseases. Despite these 
observations, studies elucidating factors regulating ALP enzymatic activity are sparse. 
Taking into account the limited knowledge regarding the regulation of ALP activity, and 
the intimate link between the intestinal microbiota, the intestine, and the liver; we 
hypothesized shifts in the microbiota composition induced by CKD may regulate the 
intestinal and liver ALP activity we observed in Chapter 3.  
 Despite observing no change in duodenum IAP activity in wild-type mice 
receiving CKD stool versus non-CKD stool, we observed increased whole duodenum 
IAP protein expression that accompanied a more intense cytoplasmic staining of 
enterocytes in the mice receiving the CKD stool (Figure 4.3). Taken together, these 
findings of higher IAP protein expression with no apparent change in enzyme activity 
would imply less enzymatic efficiency of the duodenum IAP protein expressed in mice 
treated with CKD stool. One possible explanation for this finding could be that gavaged 
CKD stool possessed more IAP protein that may regulate host IAP expression. 
However, immunoblotting of the cecal content administered to these animals showed no 
detectable IAP expression, and these mice were sacrificed one week after the last 
treatment, likely allowing for sufficient clearance of any exogenous IAP protein that was 
delivered to these animals. In current studies, we are actively treating mice with oral IAP 
therapy and plan to examine the effect of exogenous IAP treatment on native 
duodenum IAP activity and protein expression.  
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An alternative explanation for these previous observations is that CKD stool may 
have promoted an environment that results in decreased IAP enzyme efficiency. Based 
on the current state of knowledge, plausible biological changes that could reduce IAP 
enzyme activity could be increases in the intestinal phosphate content (159), disruption 
of the luminal pH, or depletion of zinc and magnesium ions required for optimal IAP 
activity. Regardless of the cause, inefficient IAP enzymatic activity may stimulate a 
response from enterocytes in the recipient host to upregulate IAP protein production; 
therefore, compensating for below average enzymatic activity that then results in equal 
total activity levels. If such a scenario were true, it would be interesting to examine 
native IAP expression and activity in Col4a3-/- (CKD) mice at an earlier time point to 
determine if IAP expression patterns of wild-type mice treated with CKD stool are 
replicated at earlier time points of CKD progression in Col4a3-/- mice. Additionally, to 
determine whether CKD mice have this theoretical compensatory mechanism, we could 
gavage CKD mice with CKD stool and measure IAP activity and protein expression. If 
this mechanism is lost in the CKD recipient mice, we could explore this loss of response 
as a possible therapeutic target.  
A final potential explanation for the observed discrepancy between duodenal IAP 
protein content and enzyme activity in CKD stool-treated mice is that this may be a 
unique response that results from prior depletion of the intestinal microbiota. The effect 
of antibiotic therapy on IAP activity in mammals is unknown; hence, the response of IAP 
activity to colonization is unknown. In the future, we could address this possibility by 
measuring IAP activity and protein expression after antibiotic therapy, as well as 
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including a group administered only PBS to explore the effect of natural re-colonization 
on IAP activity.  
Future in vitro studies will allow us to delve further into the regulation of IAP 
activity. As an initial step to better understand the regulation of IAP activity, we could 
utilize a cell culture model of enterocyte differentiation, in which sodium butyrate is 
applied to HT-29 that results in the transactivation of the IAP gene (160,161). This 
system would allow us to explore whether a circulating factor increased in the serum of 
CKD patients may regulate IAP activity. If culturing these cells with uremic serum 
suggested a circulating factor was indeed present, we could use this system to further 
explore the contribution of individual uremic toxins, especially those of intestinal origin. 
In addition to uremic toxins, CKD patients have increased circulating levels of the 
secondary bile acid deoxycholic acid (DCA) compared to non-CKD controls (162). DCA 
is generated in the intestinal lumen by the bacterial metabolism of the primary bile acid, 
cholic acid. If we observed DCA to diminish IAP activity in vitro, we could design in vivo 
experiments in which we orally administer DCA to CKD mice.  
Our other notable finding in these fecal transplant experiments was a significant 
increase in hepatic ALP activity in the wild-type mice receiving CKD stool compared to 
those receiving non-CKD stool (Figure 4.5). These increases in ALP activity was 
accompanied by increased TNAP gene expression, and increased IHC hepatic staining 
with the IAP antibody. Interestingly, the mice receiving the non-CKD stool had a distinct 
staining pattern around portal triads, and IAP nuclear staining was a common 
observation. While we speculated that this increased liver ALP activity may be due to 
increased bacterial translocation in mice receiving CKD stool, we did not observe an 
	 74 
increase in the expression of inflammatory markers in the liver (Figure 4.4)	that would 
be expected to accompany endotoxin migration into the portal circulation. Additionally, 
IP injection of LPS resulted in decreased hepatic ALP activity, possibly due to the 
production of inflammatory cytokines which are known to inhibit the activity of other ALP 
isoforms (155). Another possible regulator induced by fecal transplant may be changes 
in bile acid concentration or metabolism. Limited studies do suggest altered bile acid 
production and transport in CKD animal models (163). A simple first step to test this 
possibility could be to stain livers for the farnesoid X receptor (FXR), a bile acid sensor, 
to determine if we see co-localization with areas of IAP staining and activity.  
As with the intestinal ALP activity, in vitro studies are necessary to delve into the 
mechanisms inducing hepatic ALP activity in the setting of kidney injury. We would use 
a similar approach as described above. First, determine whether a circulating factor in 
the serum of CKD patients or animals can increase hepatic ALP activity. If so, we would 
then examine the effect of uremic toxins on ALP activity. Any uremic toxin that may 
result in upregulation of liver ALP activity can then be injected into mice to determine 
whether a similar response is induced in vivo.  
To explore the translational aspect of our findings, we could produce ‘humanized’ 
mice, as previously described (164,165). In such a study, fecal samples from non-CKD 
and CKD patients would be used to perform fecal transplant studies in mice. However, 
one major difference with these studies would be the origin of the fecal content, as 
human stool would be colon origin, whereas our described studies in mice utilized cecal 
stool samples. Stool from these two sites would not only be expected to differ in the 
microbial composition, but would likely also contain numerous other substances specific 
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to the intestinal origin of the fecal contents. Moreover, since the intestinal microbiota 
composition of mice and humans varies drastically (166), it is unclear if even human 
cecal contents could elicit a similar response to that from mice.  
The current work has both strengths and weaknesses. The most notable strength 
is that this is the first study to examine whether the intestinal microbiota of CKD animals 
can transfer a pathological phenotype and regulate ALP activity. A significant limitation 
of our studies is a lack of understanding of the mechanisms driving the observed 
changes in ALP activity. We plan to sequence the recipient mouse stool samples to 
determine whether the intestinal microbiota composition differs between mice treated 
with CKD versus non-CKD stool. This analysis could provide additional data to support 
a role of the microbial composition in regulating these ALP responses and possibly gut 
barrier function. As we have obtained intriguing results with this initial study, we will 
need to design more rigorous future studies which will test the effect of antibiotic 
therapy itself on ALP activity, and possibly include a cohort of mice that receive vehicle 
treatment alone (PBS) to determine the effect of natural re-colonization of the gut on 
ALP activity. Lastly, it will be important to repeat these experiments with stool collected 
from other animals to ensure the observed effect is not limited to just the individual mice 
used to make these fecal slurries.  
In summary, this is the first study to show evidence that transplant of a CKD 
intestinal microbiota can regulate ALP activity within the intestine and the liver. If future 
studies confirm the clinical significance of IAP in regulating the intestinal barrier in CKD, 
these studies will provide valuable mechanistic insight into the regulation of duodenum 
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CHAPTER 5: DISCUSSION 
TMAO Summary 
In this dissertation, I have provided evidence in an adenine-induced model of 
CKD that the accumulation of circulating TMAO may be partially related to increased 
hepatic generation of this compound through increased FMO activity. Our data, 
combined with prior evidence suggesting that shifts in the intestinal microbiota may also 
contribute to increased production of TMAO in CKD (118), supports the notion that high 
circulating TMAO concentrations that accompany CKD progression may not be fully 
attributable to dysfunctional renal clearance of TMAO. If future studies continue to 
support TMAO as a direct contributor to cardiovascular disease in CKD, our findings 
provide evidence for hepatic FMO activity as a potential target for lowering serum 
TMAO concentrations. Such therapies could be especially beneficial in ESRD patients, 
as this population frequently exhibits TMAO levels that are 30 to 100-fold higher than 
individuals with intact kidney function.  
TMAO Limitations 
While there is early evidence for a correlation between TMAO and adverse CVD 
events in CKD patients, evidence that reducing TMAO concentrations alters CVD 
outcomes in this population has not yet been demonstrated. Since CKD is associated 
with the accumulation of an array of uremic toxins, it will be important to conduct future 
animal studies to determine whether TMAO is truly involved in CVD progression. Such 
experiments would be crucial to understanding whether TMAO is truly a modifiable CVD 
risk factor that is worthy of targeting with future therapeutics aimed at reducing CVD 
burden in patients with CKD. In addition to the effect of TMAO directly on CVD 
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progression, our studies described in Chapter 2 neglected to investigate the 
mechanisms contributing to increased hepatic FMO activity in CKD.   
TMAO Future Work 
Translational experiments in CKD mice aimed at evaluating the direct 
contribution of TMAO to CVD progression would help provide critical justification for the 
potential clinical significance of TMAO elevations to adverse cardiovascular outcomes in 
humans with CKD. Prior studies suggest that kidney disease exacerbates 
atherosclerosis development in the ApoE-/- mouse model of atherosclerosis (167) and 
results in the development of cardiac hypertrophy (168). As TMAO is implicated in the 
development of both of these diseases in non-CKD models, it would be of interest to 
determine if reductions in TMAO in ApoE-/- mice with CKD alters these cardiovascular 
endpoints. As other gut-derived toxins besides TMAO have known pathological effects 
on the cardiovascular system, therapies targeting solely TMAO generation will be 
necessary to determine the specific contribution of TMAO to disease development. 
Targeting gut microbes with broad spectrum antibiotic treatment would likely result in 
the lowering of multiple gut-derived uremic toxins; thus, studies could be designed using 
compounds known to specifically inhibit the bacterial enzymes involved in TMA 
generation from its dietary precursors, choline and L-carnitine. One such example is 
3,3-dimethyl-1-butanol (DMB), a compound that inhibits the bacterial conversion of 
choline to TMA (120). 
The most noteworthy finding of our study was that induction of kidney disease in 
both male and female mice led to increased hepatic FMO activity. This finding 
generates several interesting future research directions: (1) to determine the factors 
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driving increased FMO activity in CKD, and (2) to explore how targeting FMO activity in 
CKD mice alters serum TMAO concentrations and clinical outcomes (i.e. survival, CKD 
progression, cardiac hypertrophy). As discussed in chapter 2, the accumulation of urea 
in CKD may be one possible driver of increased FMO activity. An alternative hypothesis 
may be that increased TMA generation resulting in increased substrate availability may 
stimulate hepatic FMO3 expression and activity. To address this possibility, we can 
assess FMO3 expression and activity in the wild-type mice that received stool content 
collected from non-CKD and CKD mice as described in Chapter 4. If a factor from the 
CKD microbiota is regulating hepatic FMO3 expression, we would expect the wild-type 
mice that received stool collected from CKD mice to have increased expression and 
activity compared to the wild-type mice that received non-CKD stool. If experiments 
reveal a direct contribution of TMAO to the development of CVD in CKD mouse models, 
studies could be conducted to determine whether inhibition of hepatic FMO activity (i.e. 
CKD induction in FMO3-/- mice) decreases TMAO accumulation and attenuates CVD 
development.  
Alkaline Phosphatase Summary 
In a separate set of studies, we examined the effect of kidney disease on ALP 
activity within both the intestine and liver. Our first notable finding was that Col4a3-/- 
mice, a model of CKD, demonstrated a significant decrease in duodenum IAP 
enzymatic activity accompanied by altered cellular localization of this protein. 
Additionally, we have preliminary IAP activity data from a second CKD mouse model 
(adenine diet), that appears to confirm these findings; however, our protein expression 
analysis in this model is still ongoing. We speculate that this decreased duodenum IAP 
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activity may contribute to intestinal barrier dysfunction in CKD. To gain insight on factors 
regulating IAP activity, we designed a fecal transplant study in which we depleted the 
microbiome of wild-type mice, then randomized these animals to be recolonized with 
stool from either non-CKD or CKD mice. We observed no change in duodenum IAP 
activity between these groups, but did find increased IAP protein expression in 
duodenal tissue from wild-type mice recolonized with CKD stool compared to those 
receiving non-CKD stool. While this result was unexpected, this may provide some 
evidence to suggest regulation of duodenum IAP production by fecal contents. 
Regardless, based on our consistent finding of decreased duodenal IAP expression and 
activity in CKD mice, IAP therapy may be a promising strategy for targeting intestinal 
barrier dysfunction in CKD. In support of this idea, IAP therapy attenuates inflammation 
in several other disease models exhibiting defects in intestinal barrier dysfunction. 
Importantly, in both mouse studies and human clinical trials conducted thus far, no 
major side-effects have been reported with IAP therapy. 
In addition to altered duodenum activity, liver ALP was convincingly increased in 
both the adenine-induced and Col4a3 mouse models of CKD. Interestingly, in the fecal 
transplant study, we observed substantially higher liver ALP activity in the wild-type 
mice receiving CKD stool compared to those that received non-CKD stool. We 
hypothesize that this upregulation of liver ALP activity in response to fecal transplant 
with CKD stool may provide evidence that constituents in CKD feces are either: (1) 
actively inducing gut barrier defects that lead to entry of bacterial toxins into portal 
blood, or (2) serving as direct regulators of liver ALP activity.  
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Our current working hypothesis is that either the accumulation of uremic toxins or 
the physiologic changes that accompany kidney disease progression (i.e. acidosis, 
mineral metabolism defects) leads to decreased IAP activity. In turn, this lack of IAP 
activity facilitates a shift in the fecal microbiota composition and defects in intestinal 
barrier integrity, possibly resulting in increased bacterial byproducts entering the portal 
circulation to stimulate liver ALP activity (Figure 5.1).     
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Figure 5.1 Working Hypothesis for ALP Activity Changes in CKD. We hypothesize 
that the uremic milieu induced by kidney injury suppresses IAP activity, which could 
lead to both changes in the relative abundance of intestinal bacteria and impaired 
intestinal barrier function. These pathologic changes could facilitate the entry of 




Alkaline Phosphatase Limitations 
 While this dissertation presents strong evidence for diminished duodenum IAP 
activity in CKD, we are unsure whether decreased IAP activity occurs before or after 
shifts in the intestinal microbiota and increased intestinal permeability. It is plausible that 
either uremia-induced microbiota shifts or decreased IAP activity could be early events 
capable of promoting altered intestinal barrier function in CKD. Furthermore, at the 
present time, we are unsure whether Col4a3-/- mice truly exhibit functional defects of the 
intestinal barrier, as this has not yet been formally studied. Lastly, the physiological 
significance of increased liver ALP activity is unknown. As the liver is a major site of 
bacterial detoxification from portal blood, we speculate that liver ALP activity is involved 
in this function; yet, further experiments will need to be performed to validate this 
hypothesis.  
Alkaline Phosphatase Future Work 
To determine the relationship between duodenum IAP activity and intestinal 
barrier function, we first need to determine whether there is a defect in intestinal barrier 
function in the Col4a3 at 10 weeks of age, the age in which we characterized IAP 
expression and activity in Chapter 3. To determine this, we can orally challenge Col4a3 
with fluorescently labeled dextran (FD4 MW 3,000-5,000), and measure the appearance 
of labeled dextran into systemic circulation. Initial studies utilizing dextran of various 
sizes will be advantageous as the extent of increased intestinal permeability in CKD 
mice is unknown. If evidence for barrier dysfunction was observed in these mice, we 
could design longitudinal studies examining the sequential relationship between IAP 
activity and intestinal barrier function along the timeline of CKD progression. 
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Additionally, these dextran gavage studies will help determine the size limit of increased 
intestinal permeability in CKD mice. To determine whether IAP can modulate microbiota 
composition in CKD mice, we will perform 16S rRNA sequencing of stool content 
collected from CKD mice randomized to receive either vehicle or IAP by oral gavage.  
Concluding Remarks  
 An ideal therapy to attenuate comorbid disease development in patients with 
CKD would modulate the inflammatory phenotype and decrease circulating levels of 
uremic toxins in patients. It may be possible that the IAP therapy could achieve both of 
these outcomes by shifting intestinal microbiota composition and fortifying the intestinal 
barrier. In addition to assessing the inflammatory profile of CKD mice treated with IAP, 
we can measure serum levels of TMAO and other uremic toxins, such as indoxyl sulfate 
and p-cresyl sulfate. However, our current lack of understanding about the mechanisms 
contributing to intestinal microenvironment changes in CKD make it difficult to design 
targeted therapies at this time.  
Several important issues need to be addressed to move the field of gut biology in 
CKD forward. First, there is still no solid published evidence that humans or animal 
models of CKD exhibit functional defects in the intestinal barrier. To date, the vast 
majority of publications merely speculate altered function based on changes in barrier 
protein expression patterns or evidence of a bacterial presence in the systemic 
circulation. Moreover, designing in vivo studies to test intestinal barrier function is not a 
simple task, as studies evaluating the emergence of labeled substances in the 
bloodstream following an oral gavage may be confounded by reduced elimination of 
these substances in the setting of kidney disease. Second, detailed investigations are 
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required to determine whether an accumulation of gut-derived uremic toxins is due to 
reduced renal clearance or shifts in the intestinal microbiota that results in increased 
capacity to generate the toxin. With advances in metagenomic sequencing, it is now 
possible to determine if specific bacterial genes which contribute to toxin production 
may be altered in bacterial populations harvested from CKD patient stool. This is a far 
more informative technique compared to traditional 16S rRNA sequencing that only 
provides data on relative bacterial abundance in a given sample. Lastly, since the 
majority of stool samples collected from patients merely reflect the bacterial populations 
present in the colon, it will be imperative to conduct future studies aimed at identifying 
bacterial changes that occur in other intestinal segments in CKD, particularly the small 
intestine. Due to difficulties with conducting such studies in humans, translational 
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